期刊文献+

半剂量替罗非班治疗老年高危不稳定型心绞痛疗效观察 被引量:4

Therapeutic effects of half dose tirofiban in the treatment of aged high-risk patients with unstable angina pectoris
下载PDF
导出
摘要 目的评价半剂量的替罗非班治疗老年高危不稳定型心绞痛的临床疗效及安全性。方法 142例老年不稳定型心绞痛患者随机分为常规治疗组(47例)、半剂量组(47例)和常规剂量组(48例),半剂量组在常规治疗组标准化治疗的基础上加用替罗非班,先给予负荷量(0.2μg·kg-1·min-1),0.5h后再以0.05μg·kg-1·min-1维持量维持48h;常规剂量组在常规治疗组标准化治疗的基础给予负荷量(0.4μg·kg-1·min-1)替罗非班0.5h后以0.1μg·kg-1·min-1维持量维持48h。观察治疗时心绞痛发作频率、程度、持续时间、硝酸甘油用量、18导联静息心电图变化以及出血事件。结果心绞痛症状总有效率:半剂量组91.49%、常规剂量组95.83%、常规治疗组76.60%,常规剂量组和半剂量组的有效率均显著高于常规治疗组(P=0.006,P=0.049)。但常规剂量组和半剂量组的有效率比较差异无统计学意义(P=0.384)。心电图疗效:经过治疗后三组患者心电图下移较治疗前均有显著性改变(P<0.01)。出血事件发生率比较:半剂量组4.26%、常规剂量组18.75%、常规治疗组2.13%,常规剂量组出血事件发生率较半剂量组和常规治疗组显著增加(P=0.027,P=0.021)。半剂量组和常规治疗组两组出血事件发生率差异无统计学意义(P>0.05)。结论应用半剂量的替罗非班治疗治疗老年高危不稳定型心绞痛,能有效缓解心绞痛症状和改善心电图,其不良反应较常规剂量组显著减少。 Objective To evaluate therapeutic effects and safety of half dose tirofiban in the treatment of aged high-risk patients with unstable angina pectoris. Methods A total of 142 aged high-risk patients with unstable angina pectoris were randomly divided into half dose group (n=47), routine dose group (n=48) and routine treatment group (a=47). Half dose group was treated by tirofiban based on standard treatment for routine treatment group, loading 0.2 μg/(kg. rain), 30-minute intravenous infusion, followed by maintenance dose 0.05 μg/(kg. min) 48-hour continuous intravenous infusion. Routine dose group was treated by tirofiban based on standard treatment for routine treatment group, loading 0.4 μg/(kg ·min), 30-minute intravenous infusion, followed by maintenance dose 0.1 μg/(kg. rain) 48-hour continuous intravenous infusion. The frequency of angina, degree, duration, nitroglycerin consumption, 18-lead ECG changes and bleeding events were observed. Results The total effective rate for symptoms of angina pectoris was 91.49 % in half dose group, 95.83% in routine dose group, 82.98% in routine treatment group. The total effective rate was significantly higher in half dose group and routine dose group than routine treatment group (P=0.006; P=049), but showed no statistically significant difference between half dose group and routine dose group (P=0.384). There is a significant difference of improvement on ECG of the three groups before and after treatment (P〈0.01). The incidence of hemorrhage was 4.25% in half dose group, 18.75% in routine dose group, 2.13% in routine treatment group. There is a significant difference in incidence of hemorrhage between half dose group and routine dose group (P=-0.027; P=-0.021), but there was no statistical difference between half dose group and routine treatment group (P〉 0.05). Conclusion Half maintenance doses oftirofiban is safe and effective in improving symptoms of angina pectoris and electrocardiogram in aged high-risk patients with unstable angina pectoris. Hyporhea in half dose group is significantly decreased than that of routine dose group.
作者 冯旭霞
出处 《海南医学》 CAS 2013年第14期2046-2049,共4页 Hainan Medical Journal
关键词 替罗非班 心绞痛 不稳定型 治疗结果 Tirofiban Angina Unstable Treatment outcome
  • 相关文献

参考文献10

二级参考文献72

共引文献2257

同被引文献29

  • 1Amane HSBurte N P.A comparative study of dalteparin and unfractionated heparin in patients with unstable angina pectoris[J].Indian Journal of Pharmacology,2011,34(6):157-159.
  • 2Li H L,Peng.Vaspin plasma concentrations and mRNA expressions in patients with stable and unstable angina pectoris[J].Clinical Chemistry and Laboratory Medicine,2011,32(9):523-526.
  • 3Jeffrey L. Anderson,Cynthia D. Adams,Elliott M. Antman,Charles R. Bridges,Robert M. Califf,Donald E. Casey,William E. Chavey,Francis M. Fesmire,Judith S. Hochman,Thomas N. Levin,A. Michael Lincoff,Eric D. Peterson,Pierre Theroux,Nanette K. Wenger,R. Scott Wright.2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction[J]. Journal of the American College of Cardiology . 2013 (23)
  • 4Yates MT,Soppa GK,Valencia O,et al.Impact of European Society of Cardiology and European Association for Cardiothoracic Surgery Guidelines on Myocardial Revascularization on the activity of percutaneous coronary intervention and coronary artery bypass graft surgery forstable coronary artery disease[J].J Thorac Cardiovasc Surg,2014,147(2):606-610.
  • 5Hannan EL,Wu C,Walford G,et al.Drug-eluting stents vs.coronary-artery bypass ^afting in multivessel coronary disease[J].NEngl J Med,2008,358(4):331-341.
  • 6Hillis LD,Smith PK,Anderson JL,et al.2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery.A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Developed in collaboration with the American Association for Thoracic Surger-y,Society of Cardiovascular Anesthesiologists,and Society of Thoracic Surgeons[J].J Am Coll Cardiol,2011,58(24):123-210.
  • 7Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopi-dogrel in patients with acute coronary syndromes[J].N Engl J Med,2009,361(11):1045-1057.
  • 8Mehran R,Rao SV,Bhatt DL,et al.Standardized bleeding definitions for cardiovascular clinical trials:a consensus report from the BleedingAcademic Research Consortium[J].Circulation,2011,123(23):2736-2747.
  • 9Kabbani SS,Watkins MW,Ashikaga T,et al.Platelet reactivity characterized prospectively:a determinant of outcome 90 days after percutaneous coronary intervention[J].Circulation,2001,104(2):181-186.
  • 10Wallentin Lars,Becker Richard C,Budaj Andrzej,Cannon Christopher P,Emanuelsson H?kan,Held Claes,Horrow Jay,Husted Steen,James Stefan,Katus Hugo,Mahaffey Kenneth W,Scirica Benjamin M,Skene Allan,Steg Philippe Gabriel,Storey Robert F,Harringt.Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England Quarterly . 2009

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部